Lowe Syndrome
1
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Genome & CompanyKorea - Suwon
1 programGenetic Analysis of Oculocerebrorenal Syndrome of LoweN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Can-Fite BioPharmaPiclidenoson
Genome & CompanyGenetic Analysis of Oculocerebrorenal Syndrome of Lowe
Clinical Trials (2)
Total enrollment: 125 patients across 2 trials
An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome
Start: Jun 2026Est. completion: Aug 20275 patients
Phase 2Not Yet Recruiting
Genetic Analysis of Oculocerebrorenal Syndrome of Lowe
Start: Feb 2001Est. completion: Feb 2009120 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.